Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock dropped 3% Friday after the company announced its cancer drug Trodelvy failed to meet its primary endpoint in a Phase 3 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback